VTRS vs MRK vs PFE vs ABBV vs MCK

For growth investors, McKesson Corporation (MCK) is the stronger pick with 16.

2% revenue growth year-over-year, versus -3. 0% for Viatris Inc. (VTRS). Merck & Co. , Inc. (MRK) offers the better valuation at 15. 4x trailing P/E (21. 7x forward), making it the more compelling value choice. Analysts rate Merck & Co. , Inc. (MRK) a "Buy" — based on 37 analyst ratings — the highest consensus in this comparison. The "better buy" depends entirely on your goals: growth investors should weight revenue trajectory, value investors should weight P/E and PEG, and income investors should weight dividend yield and streak.

On trailing P/E, Merck & Co.

, Inc. (MRK) is the cheapest at 15. 4x versus AbbVie Inc. at 85. 5x. On forward P/E, Viatris Inc. is actually cheaper at 7. 0x — notably different from the trailing picture, reflecting expected earnings growth. The PEG ratio (P/E divided by earnings growth rate) is the most growth-adjusted single valuation metric: McKesson Corporation wins at 0. 43x versus Merck & Co. , Inc. 's 1. 02x — a PEG below 1. 0 traditionally signals the market is underpricing earnings growth.

Over the past 5 years, McKesson Corporation (MCK) delivered a total return of +286.

9%, compared to -13. 3% for Pfizer Inc. (PFE). Over 10 years, the gap is even starker: MCK returned +339. 0% versus VTRS's -52. 1%. Past returns do not guarantee future results, and the stock with the higher historical return may already have its best growth priced in.

By beta (market sensitivity over 5 years), McKesson Corporation (MCK) is the lower-risk stock at -0.

02β versus Viatris Inc. 's 0. 94β — meaning VTRS is approximately -5843% more volatile than MCK relative to the S&P 500. On balance sheet safety, Pfizer Inc. (PFE) carries a lower debt/equity ratio of 78% versus 100% for Viatris Inc. — giving it more financial flexibility in a downturn.

By revenue growth (latest reported year), McKesson Corporation (MCK) is pulling ahead at 16.

2% versus -3. 0% for Viatris Inc. (VTRS). On earnings-per-share growth, the picture is similar: McKesson Corporation grew EPS 14. 9% year-over-year, compared to -466. 0% for Viatris Inc.. Over a 3-year CAGR, MCK leads at 10. 8% annualised revenue growth. Higher growth typically commands a higher valuation multiple — check whether the premium P/E or P/S is justified by the growth rate using the PEG ratio.

Merck & Co.

, Inc. (MRK) is the more profitable company, earning 28. 1% net margin versus -24. 6% for Viatris Inc. — meaning it keeps 28. 1% of every revenue dollar as bottom-line profit. Operating margin tells a similar story: MRK leads at 36. 2% versus -18. 6% for VTRS. At the gross margin level — before operating expenses — MRK leads at 72. 0%, reflecting greater pricing power or product mix advantage. Stronger margins indicate durable pricing power, lower cost of revenue, or higher mix of software/services. They are one of the clearest signs of business quality.

The PEG ratio (forward P/E divided by expected earnings growth rate) is the most precise measure of undervaluation relative to growth potential.

By this metric, McKesson Corporation (MCK) is the more undervalued stock at a PEG of 0. 43x versus Merck & Co. , Inc. 's 1. 02x. A PEG below 1. 0 is traditionally considered the threshold for growth-adjusted undervaluation. On forward earnings alone, Viatris Inc. (VTRS) trades at 7. 0x forward P/E versus 21. 7x for Merck & Co. , Inc. — 14. 7x cheaper on a one-year earnings basis. Analyst consensus price targets imply the most upside for MCK: 32. 2% to $994. 86.

All stocks in this comparison pay dividends.

Pfizer Inc. (PFE) offers the highest yield at 6. 5%, versus 0. 4% for McKesson Corporation (MCK).

For long-horizon retirement investors, AbbVie Inc.

(ABBV) is the stronger choice — it scores higher on the combination of lower volatility, dividend reliability, and long-term compounding (low volatility (β 0. 28), 3. 2% yield, +293. 8% 10Y return). Both have compounded well over 10 years (ABBV: +293. 8%, VTRS: -52. 1%), confirming both are viable long-term holds — but the lower-volatility option typically results in less emotional selling during corrections. Retirement portfolios generally favour predictability over maximum returns. Consult a financial advisor before making allocation decisions.

Both stocks operate in the Healthcare sector, making this a peer-level intra-sector comparison — the same macro tailwinds and headwinds will affect both.

In terms of investment character: VTRS is a mid-cap quality compounder stock; MRK is a large-cap deep-value stock; PFE is a mid-cap income-oriented stock; ABBV is a large-cap income-oriented stock; MCK is a mid-cap high-growth stock. VTRS, MRK, PFE, ABBV pay a dividend while MCK does not, making them suitable for different income and tax situations. These fundamental differences mean investors should not choose between them on a single metric — the "better stock" depends entirely on which of these characteristics aligns with your investment strategy.